Research programme: mesenchymal tumours RNA therapeutics - Arpeggio biosciences
Alternative Names: mesenchymal tumours therapeutics - Arpeggio biosciencesLatest Information Update: 15 May 2023
At a glance
- Originator Arpeggio Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Malignant melanoma; Sarcoma; Triple negative breast cancer
Most Recent Events
- 12 May 2023 Early research in Sarcoma in USA (Parenteral) (Arpeggio Biosciences pipeline, May 2023)
- 12 May 2023 Early research in Triple-negative-breast-cancer in USA (Parenteral) (Arpeggio Biosciences pipeline, May 2023)
- 12 May 2023 Early research in Malignant melanoma in USA (Parenteral) (Arpeggio Biosciences pipeline, May 2023)